SI23130A - Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds - Google Patents
Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds Download PDFInfo
- Publication number
- SI23130A SI23130A SI200900262A SI200900262A SI23130A SI 23130 A SI23130 A SI 23130A SI 200900262 A SI200900262 A SI 200900262A SI 200900262 A SI200900262 A SI 200900262A SI 23130 A SI23130 A SI 23130A
- Authority
- SI
- Slovenia
- Prior art keywords
- milk
- uric acid
- purine
- draught
- composite
- Prior art date
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 106
- 239000008267 milk Substances 0.000 title claims abstract description 106
- 210000004080 milk Anatomy 0.000 title claims abstract description 106
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 59
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 229940116269 uric acid Drugs 0.000 title claims abstract description 59
- 235000005911 diet Nutrition 0.000 title claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 230000000378 dietary effect Effects 0.000 title claims abstract description 12
- 239000002131 composite material Substances 0.000 title claims abstract description 8
- 230000002829 reductive effect Effects 0.000 title claims abstract description 5
- 150000003212 purines Chemical class 0.000 title abstract description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 40
- 235000021243 milk fat Nutrition 0.000 claims abstract description 14
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 10
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 9
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 5
- 239000011782 vitamin Substances 0.000 claims abstract description 5
- 229930003231 vitamin Natural products 0.000 claims abstract description 5
- 235000013343 vitamin Nutrition 0.000 claims abstract description 5
- 229940088594 vitamin Drugs 0.000 claims abstract description 5
- 229930064664 L-arginine Natural products 0.000 claims abstract description 4
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 4
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 65
- 230000008569 process Effects 0.000 claims description 16
- 239000000654 additive Substances 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 230000037213 diet Effects 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000020124 milk-based beverage Nutrition 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 235000013365 dairy product Nutrition 0.000 abstract description 12
- 238000001179 sorption measurement Methods 0.000 abstract description 11
- 238000004806 packaging method and process Methods 0.000 abstract description 9
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract description 8
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 7
- 238000000265 homogenisation Methods 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000008030 elimination Effects 0.000 abstract description 6
- 238000003379 elimination reaction Methods 0.000 abstract description 6
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 abstract description 6
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 5
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 150000003230 pyrimidines Chemical class 0.000 abstract description 5
- 239000002777 nucleoside Substances 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 3
- 229930024421 Adenine Natural products 0.000 abstract description 3
- 239000002211 L-ascorbic acid Substances 0.000 abstract description 3
- 229960000643 adenine Drugs 0.000 abstract description 3
- 125000003835 nucleoside group Chemical group 0.000 abstract description 3
- 230000009858 acid secretion Effects 0.000 abstract description 2
- 238000005119 centrifugation Methods 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 239000005547 deoxyribonucleotide Substances 0.000 abstract description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 abstract description 2
- 230000002427 irreversible effect Effects 0.000 abstract description 2
- 210000000738 kidney tubule Anatomy 0.000 abstract description 2
- 230000008092 positive effect Effects 0.000 abstract description 2
- 239000002719 pyrimidine nucleotide Substances 0.000 abstract description 2
- 210000005239 tubule Anatomy 0.000 abstract description 2
- 239000003610 charcoal Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 14
- 108010093894 Xanthine oxidase Proteins 0.000 description 13
- 102100033220 Xanthine oxidase Human genes 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 235000020247 cow milk Nutrition 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 235000019645 odor Nutrition 0.000 description 4
- 239000002213 purine nucleotide Substances 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000020251 goat milk Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000001234 nutrigenomic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000020881 DASH diet Nutrition 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 230000008848 allosteric regulation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940086761 arginine 500 mg Drugs 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940019910 coenzyme Q10 200 mg Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 235000020603 homogenised milk Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 150000007971 urates Chemical class 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Področje tehnike na katero se iznajdba nanašaFIELD OF THE INVENTION
Prehrambena tehnologija, dietetični preparatiFood technology, dietetic preparations
Tehnični problemA technical problem
Putika je bolezen, ki jo spremljajo močne bolečine in komplikacije zaradi nabiranja in sedimentiranja sečne kisline ali njenih soli uratov. Terapija se sastoji iz dajanja zdravil, ki inhbiirajo produkcijo sečne kisline in „apurinski dieti, ki ne vsebuje živil bogatih s purini, pred vsem mesa, mesnih izdelkov in drobovine. Mleko se priporoča kot edini izvor polnovrednih beljakovin. Problem takšne rešitve je v dejstvu da je mleko v veliki meri bogato z nukleinskimi kislinami, kot tudi z derivati mononukleotidnega in nukleozidnega značaja, oziroma s prostimi bazami purinskega tipa (hipoksantin, ksantin), zlasti pa s samo sečno kislino! Sečna kislina, ki je nastala v črevesju ali prispela iz hrane, se v človeškem organizmu naprej ne metabolizira in se resorbira v krvni obtok!Putica is a disease that is accompanied by intense pain and complications due to the accumulation and sedimentation of uric acid or its urate salts. Therapy consists of the administration of medicines that inhibit the production of uric acid and the 'apurine diet, which does not contain purine-rich foods, above all meat, meat products and offal. Milk is recommended as the sole source of whole protein. The problem with this solution lies in the fact that milk is largely rich in nucleic acids, as well as with mononucleotide and nucleoside derivatives, or with free bases of purine type (hypoxanthine, xanthine), and in particular uric acid itself! Uric acid, which is formed in the gut or arrived from food, is not further metabolized in the human body and is absorbed into the bloodstream!
Stanje tehnike v svetu in pri nasState of the art in the world and in our country
Količina sečne kisline v vzorcih kravjega mleka, se po podatkih v literaturi giba okrog 200 pmol/L, v ostalih purinskih bazah pa do 20 pmol/L. Mleko je bogato z nizom purinskih ribonukelotidov, substratov za encime nukleaze, ki so tudi v mleku, posebej pa v digestivnem traktu. Količina prisotnih ribonukleotidov v obliki polinukleotida in oligonukleotida po podatkih v literaturi znaša okrog 68 +/- 55 pmol/L, kot mononukleotida 84 +/- 25 pmol/L in okrog 10 +/- 2 pmol/L kot nukleozida. Dokazana je tudi določena količina prostih purinskih baz, kot sta hipoksantin in ksantin do 20 pmol/L. Navedeni derivati so neminovno podvrženi hidrolitični razgradnji v črevesju, kar pomeni, da je okrog 200 pmol/L minimalna količina sečne kisline, ki se lahko producira in/ali vnese z uživanjem 1L mleka.According to the literature, the amount of uric acid in cow's milk samples ranges from about 200 pmol / L and up to 20 pmol / L in other purine bases. Milk is rich in a variety of purine ribonucleotides, substrates for nuclease enzymes, which are also found in milk and specifically in the digestive tract. The amount of ribonucleotides present in the form of polynucleotide and oligonucleotide according to the literature is about 68 +/- 55 pmol / L, as 84 +/- 25 pmol / L mononucleotide, and about 10 +/- 2 pmol / L as nucleoside. A certain amount of free purine bases such as hypoxanthine and xanthine up to 20 pmol / L has also been demonstrated. These derivatives are inevitably subject to hydrolytic degradation in the gut, which means that around 200 pmol / L is the minimum amount of uric acid that can be produced and / or introduced by consuming 1L of milk.
Vsebina sečne kisline varira v vzorcih mleka, toda ni pod 100 pmol/L, čeprav naši podatki potrjujejo, da manipulacije, ki aktivirajo ksantin oksidazo (homogeniziranje) ali preiskus v polnomastnem, neobranem mleku, dajejo visoke vrednosti sečne kisline, ki se gibajo tudi do 300 pmol/L. Naši podatki varirajo v odvisnosti od specifičnosti metodologije kot tudi tipa mleka. Ker smo dobili okrog 330 pmol/L v vzorcih mleka, ko je narejena spektrofotometrijska tehnika, se je pristopilo k bolj natančni hromatogarfski tehniki, oz. HPLC metodi. Rezultati so pokazali, da se vrednosti sečne kisline gibajo od 100-200 pmol/L za sečno kislino, dočim je koncentracija purinskih baz (adenina, hipoksantina, ksantina in guanina) in baz v okviru ribonukleinskih kislin do 50 pmol/L. V tabeli 1 so prikazane vrednosti sečne kisline, merjene s HPLC metodo ob prisotnosti ustreznega standarda v kravjem mleku po različnih nadmorskih višinah pridelave.Uric acid content varies in milk samples, but it is not below 100 pmol / L, although our data confirm that manipulations that activate xanthine oxidase (homogenization) or testing in whole, whole milk yield high uric acid values, which also move up to 300 pmol / L. Our data vary depending on the specifics of the methodology as well as the type of milk. Since we obtained about 330 pmol / L in milk samples when a spectrophotometric technique was performed, a more accurate chromatographic technique was used, respectively. HPLC method. The results showed that uric acid values range from 100-200 pmol / L for uric acid, resulting in concentrations of purine bases (adenine, hypoxanthine, xanthine and guanine) and bases within ribonucleic acids up to 50 pmol / L. Table 1 shows the uric acid values measured by the HPLC method in the presence of an appropriate standard in cow's milk at different production altitudes.
Mleko je zelo bogato s ksantin oksidazo, ključnim encimom produkcije sečne kisline, iz katere je prvič in izolorana in proučena. Komercialni preparati prečiščene ksantin oksidaze se tudi sedaj proizvajajo iz mleka. Kot močen producent prostih radikalov deluje baktericidno, toda njena škodljivost se odraža v veliki produkciji sečne kisline iz dostopnih egzogenih substratov. Upoštevajoč tudi veliko bogatstvo mleka v purinskih ribonukleotidih, kot tudi v nukleazah, je jasno, da stopnja manipulacije z vzorcem, kot je dolžina homogeniziranja in temperatura, v veliki meri prispevajo k porastu količine nukleozidov, prostih baz in sečne kisline v mleku.Milk is very rich in xanthine oxidase, the key enzyme in uric acid production from which it is first isolated and studied. Commercial preparations of purified xanthine oxidase are still produced from milk. As a powerful producer of free radicals, it acts bactericidal, but its harmfulness is reflected in the large production of uric acid from accessible exogenous substrates. Considering also the high abundance of milk in purine ribonucleotides as well as in nucleases, it is clear that the degree of manipulation of the sample, such as the length of homogenization and temperature, greatly contributes to the increase in the amount of nucleosides, free bases and uric acid in milk.
Načini izolacije purinskih nukleotidov iz mleka so v glavnem imeli za cilj bolj natančno determinacijo tipa prisotnih purinskih in pirimidinskih baz, kar pomeni, da so omenjeni izključno v raziskovalne namene, vendar ne tudi z namenom izolacije ali eliminacije iz hrane, tj. dietetske namene. V literaturi se kot način izolacije iz mleka opisuje tehnika izolacije purinskih baz na jonoizmenjevalni koloni. Priprava kolone je po rutinski proceduri polnjenja s katjonsko smolo, najpogosteje DOWEX tipa, ki veže na sebe anjone, kot je sečna kislina. Da bi se izolirale omenjene baze je nujno, da se predhodno opravi deproteinizacija vzorca. V kolikor se ne bi opravila deproteinizacija, bi katjonska smola vezala tudi proteine iz mleka, ki tudi vsebujejo anjonske lastnosti, s čemer bi se zmanjšala stopnja prečiščenosti vzorca na koloni, toda v širšem, uporabnem smislu, mleko bi bilo osiromašeno s proteini. Zaradi tega ima ta metoda v glavnem le analitični pomen. V proceduri analize vrste in značilnosti purinskih baz in derivatov v mleku smo koristili tehnike hromatografije HPLC, takrat pa je vzorec mleka moral biti predhodno deproteinizaran.The methods of isolation of purine nucleotides from milk were mainly aimed at a more precise determination of the type of purine and pyrimidine bases present, meaning that they were mentioned solely for research purposes but not for the purpose of isolation or elimination from food, ie. dietary purposes. In the literature, a technique for isolating purine bases on an ion-exchange column has been described as a method of isolation from milk. Column preparation is a routine cationic resin filling procedure, most commonly a DOWEX type that binds itself to anions such as uric acid. In order to isolate said bases, it is essential that the sample be deproteinized beforehand. Unless deproteinization was performed, the cationic resin would also bind milk proteins that also have anionic properties, thereby reducing the degree of purification of the sample on the column, but in a broader, applicable sense, milk would be depleted of proteins. For this reason, this method is mainly of analytical importance. HPLC chromatography techniques were used in the procedure for analyzing the nature and characteristics of purine bases and derivatives in milk, but at that time the milk sample had to be deproteinized beforehand.
Druge oblike izolacije sečne kisline razumevajo tehnike dialize. V tem smislu se iz mleka lahko nespecifično izolira večina malih, difuzibilnih molekul, kot so laktoza, urea, sečna kislina, kreatinin, amino kisline in joni. Tehnika je zahtevna, v kolikor se izvaja pod laboratorijskimi pogoji, saj je nujna prisotnost aparata dijalizatorja s specifičnimi dijalizerji za male molekule. Ta metoda se v medicini ne more prezreti, saj pacienti z ledvično insuficijenco, ki imajo porast sečne kisline preko 700 pmol/L in spremljajočo ledvično insuficijenco, po opravljeni dializi, pomembno zmanjšajo koncentracije sečne kisline v plazmi, kot tudi ureo. Če bi se mleko podvrglo dializi v pogojih proizvodnje, to pomeni, da bi mlekarna morala imeti aparat dializator, kot tudi pripravljeno dializno tekočino, kar bi podražilo proces proizvodnje. V kolikor se dializa mleka izvaja v adaptiranih pogojih, z uporabo dializne membrane iz celofana ob dializni tekočini, ki ne bo imela anjonov druge vrste, ampak samo hidroksilne skupine (zaradi Donanovega zakona), dializa daje slabe rezultate, ker ni zagotovljen pritisk, niti kontinuirani pretok dializne tekočine. Poleg tega je mleko izpostavljeno zunanjim vplivom v odprtem sistemu in zaradi tega omenjena metoda ni povsem primerna za tehnološki postopek izolacije sečne kisline v industriji.Other forms of uric acid isolation understand dialysis techniques. In this sense, most small, diffusible molecules such as lactose, urea, uric acid, creatinine, amino acids and ions can be isolated from milk non-specific. The technique is demanding insofar as it is carried out under laboratory conditions, since the presence of a dialysis machine with specific small molecule dialysers is necessary. This method cannot be ignored in medicine, since patients with renal insufficiency with uric acid increase above 700 pmol / L and accompanying renal insufficiency, after dialysis, have a significant decrease in plasma uric acid concentrations as well as urea. If the milk were to undergo dialysis under production conditions, it would mean that the dairy would need to have a dialyzer apparatus as well as a ready dialysis fluid, which would make the production process more expensive. To the extent that milk dialysis is performed under adapted conditions, using a dialysis membrane made of cellophane with a dialysis fluid that will have no anions of another type but only a hydroxyl group (due to Donan's law), dialysis produces poor results because neither pressure nor continuous dialysis fluid flow. In addition, the milk is exposed to external influences in an open system and as a result, the aforementioned method is not entirely suitable for the industrial uric acid isolation process.
Uporabljene reference:References used:
1. Tiemeyer W, Stohrer M, Giesecke D. Metabolites of Nucleic Acids in Bovine1. Tiemeyer W, Stohrer M, Giesecke D. Metabolites of Nucleic Acids in Bovine
Milk. Journal of Dairy Science Vol. 67, No. 4, 1984Milk. Journal of Dairy Science Vol. 67, No. 1 4, 1984
2. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA 1991;266:3004-3007.2. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004-3007.
2. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the2. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the
National Health and Nutrition Examination Survey lil, 1988-1994. Am J KidneyNational Health and Nutrition Examination Survey lil, 1988-1994. Am J Kidney
Dis 2002;40:37-42.Dis 2002; 40: 37-42.
3. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-451.3. Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445-451.
4. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol4. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol
2002;29:1350-1355.2002; 29: 1350-1355.
5. Gibson T, Rodgers AV, Simmonds HA, Court-Brown F, Todd E, Meilton V. A controlled study of diet in patients with gout. Ann Rheum Dis 1983;42:123127.5. Gibson T, Rodgers AV, Simmonds HA, Court-Brown F, Todd E, Meilton V. A controlled study of diet in patients with gout. Ann Rheum Dis 1983; 42: 123127.
6. Matzkies F, Berg G, Madl H. The uricosuric action of protein in man. Adv Exp Med Biol 1980;122:227-231.6. Matzkies F, Berg G, Madl H. The uricosuric action of a protein in man. Adv Exp Med Biol 1980; 122: 227-231.
7. Loenen HM, Eshuis H, Lowik MR, et al. Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch Nutrition Surveillance System). J Ciin Epidemiol 1990;43:12971303.7. Loenen HM, Eshuis H, Lowik MR, et al. Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch Nutrition Surveillance System). J Ciin Epidemiol 1990; 43: 12971303.
8. Garrel DR, Verdy M, PetitClerc C, Martin C, Brule D, Hamet P. Milk- and soyprotein ingestion: acute effect on serum uric acid concentration. Am J Ciin Nutr 1991;53:665-669.8. Garrel DR, Verdy M, PetitClerc C, Martin C, Brule D, Hamet P. Milk- and soyprotein ingestion: an acute effect on serum uric acid concentration. Am J Ciin Nutr 1991; 53: 665-669.
9. Ghadirian P, Shatenstein B, Verdy M, Hamet P. The influence of dairy Products on plasma uric acid in women. Eur J Epidemiol 1995;11:275-281.9. Ghadirian P, Shatenstein B, Verdy M, Hamet P. The influence of dairy products on plasma uric acid in women. Eur J Epidemiol 1995; 11: 275-281.
10. Clifford AJ, Riumallo JA, Young VR, Scrimshaw NS. Effect of oral purines on serum and urinary uric acid of normal, hyperuricemic and gouty humans. J Nutr 1976;106:428-434.10. Clifford AJ, Riumallo JA, Young VR, Scrimshaw NS. Effect of oral purines on serum and urinary uric acid of normal, hyperuricemic and gouty humans. J Nutr 1976; 106: 428-434.
11. Zollner N, Griebsch A. Diet and gout. Adv Exp Med Biol 1974;41:435-442.11. Zollner N, Griebsch A. Diet and gout. Adv Exp Med Biol 1974; 41: 435-442.
12. Griebsch A, Zollner N. Effect of ribomononucleotides given oralty on uric acid production in man. Adv Exp Med Biol 1974;41:443-449.12. Griebsch A, Zollner N. Effect of ribomononucleotides given orally on uric acid production in man. Adv Exp Med Biol 1974; 41: 443-449.
13. Roubenoff R. Gout and hyperuricemia. Rheum Dis Ciin North Am 1990; 16:539550.13. Roubenoff R. Gout and hyperuricemia. Rheum Dis Ciin North Am 1990; 16: 539550.
14. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-426.14. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-426.
15. Nugent CA. Renal urate excretion in gout studied by feeding ribonucleic acid. Arthritis Rheum 1965;8:671-685.15. Nugent CA. Renal urate excretion and gout studied by feeding ribonucleic acid. Arthritis Rheum 1965; 8: 671-685.
16. Gibson T, Highton J, Potter C, Simmonds HA. Renal impairment and gout. Ann Rheum Dis 1980;39:417-423.16. Gibson T, Highton J, Potter C, Simmonds HA. Renal impairment and gout. Ann Rheum Dis 1980; 39: 417-423.
17. Glynn RJ, Campion EW, Silbert JE. Trends in serum uric acid levels 1961-1980. Arthritis Rheum 1983;26:87-93.17. Glynn RJ, Campion EW, Silbert JE. Trends in serum uric acid levels 1961-1980. Arthritis Rheum 1983; 26: 87-93.
18. Raiziss GW, Dubin H, Ringer Al. Studies in endogenous uric acid metabolism. J Biol Chem 1914;19:473-485.18. Raiziss GW, Dubin H, Ringer Al. Studies in endogenous uric acid metabolism. J Biol Chem 1914; 19: 473-485.
19. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of vveight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000;59:539-543[PMC free article] [PubMed] 19. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of evening loss associated with moderate calorie / carbohydrate restriction, and increased proportional protein intake and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539-543
20. Shadick NA, Kirn R, Weiss S, Liang MH, Sparrow D, Hu H. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the Normative Aging Study. J Rheumatol 2000;27:1708-1712.[PMC free article] [PubMed] 20. Shadick NA, Kirn R, Weiss S, Liang MH, Sparrow D, Hu H. The effect of low-level lead exposure on hyperuricemia and gout among middle aged and elderly men: the Normative Aging Study. J Rheumatol 2000; 27: 1708-1712.
21. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Ciin Epidemiol 1988;41:237-242.21. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Ciin Epidemiol 1988; 41: 237-242.
22. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout: the role of hypertension. Arthritis Rheum 1995;38:628-632.22. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout: the role of hypertension. Arthritis Rheum 1995; 38: 628-632.
23. Sharpe CR. A case-control study of alcohol consumption and drinking behaviour in patients with acute gout. Can Med Assoc J 1984;131:563-567.23. Sharpe CR. A case-control study of alcohol consumption and drinking behavior in patients with acute gout. Can Med Assoc J 1984; 131: 563-567.
24. Kearns J. Charcoal Filtration Basics 2007; 1-7.24. Kearns J. Charcoal Filtration Basics 2007; 1-7.
Choi HK, Atkinson K, Karlso EW, Willett W, Curhan G. Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men.N Engl J Med. 2004; 350:1093-1103Choi HK, Atkinson K, Karlso EW, Willett W, Curhan G. Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men.N Engl J Med. 2004; 350: 1093-1103
Opis nove rešitveDescription of the new solution
Predstavljen tehnični problem rešuje kompozitni dietetični mlečni napitek in postopek za proizvodnjo kompozitnega dietetičnega mlečnega napitka z reduciranim nivojem sečne kisline in purina. Napitek po izumu ima naslednje lastnosti:The present technical problem solves the composite dietary milk beverage and the process for the production of composite dietary milk beverage with reduced uric acid and purine levels. The beverage of the invention has the following characteristics:
• da se maksimalno eliminira sečna kislina, nukleinske kisline, nukleotidi in proste baze purinskega tipa iz mleka • vsebuje substance, ki bodo omogočile boljšo eliminacijo sečne kisline ledvicam- da se sproži tako imenovani urikozurični efekt • da se eliminirajo težke kovine, ki delujejo toksično in uničujoče na tubulski sistem in so dodatni razlog hiperurikemije, saj onemogočajo aktivne sekrecije sečne kisline • da se maksimalno eliminira prisotna ksantin oksidaza, s katero je mleko zelo bogato, da bi preostala količina bila v največi meri nepovratno inhibirana in, da prisotnost naravnih inhibitorjev ksantin oksidaze zmanjša akivnost tega encima v črevesju.• to maximize the elimination of uric acid, nucleic acids, nucleotides and free bases of purine type from milk • contains substances that will allow better elimination of uric acid by the kidneys- to trigger the so-called uricosuric effect • to eliminate heavy metals that have toxic and toxic effects. destructive to the tubular system and are an additional cause of hyperuricemia as they inhibit the active secretion of uric acid • to minimize the presence of xanthine oxidase, which is very rich in milk, to a maximum extent irreversibly inhibited, and to the presence of natural xanthine oxidase inhibitors decreases the activity of this enzyme in the gut.
• vsebuje antioksidante, ki bodo imeli lastnost, da zmanjšajo oksidativni stres in naravno inhibirajo ksantin oksidazo.• contains antioxidants that will have the property of reducing oxidative stress and naturally inhibiting xanthine oxidase.
Postopek po izumu izpolnjuje pogoje za pridobitev zgoraj zapisanih lastnosti ciljem, da na netoksičen način, v čim večji meri odstrani sečno kislino, kot tudi purinske • · ribonukleotide, dezoksiribonukleotide, nukleozide in proste purinske baze (adenin in guanin), ki so prisotne v mleku. Ta tip dietičnega mlečnega napitka lahko uživajo brez kakršnekoli nevarnosti vse osebe, je pa prvenstveno namenjen osebam s putiko in povečano vsebino sečne kisline v krvi.The process according to the invention fulfills the conditions for obtaining the abovementioned properties in order to eliminate uric acid as much as possible in a non-toxic manner, as well as purine • ribonucleotides, deoxyribonucleotides, nucleosides and free purine bases (adenine and guanine) present in milk . This type of diet milk drink can be enjoyed without any danger by all persons, but is primarily intended for people with gouty and increased uric acid content in the blood.
Tehnika izolacije purinskih baz in nukleotidov z aktivnim ogljem se je v raziskovalnih pogojih pokazala kot neuporabna, saj je ustvarjanje adsorpcije sečne kisline in purinskih baz tako stabilno, da se le-te ne morejo eluirati z adsorbensa niti z bolj agresivnimi tretmaji (kot je NaOH), oziroma detektirati in kvantificirati. Ravno to je moment, ki je v naših pogojih separacije sečne kisline iz mleka koristen, ker tako visoka afiniteta onemogoča sproščanje purinskih baz in sečne kisline iz mleka in zaradi tega maksimalno učinkuje. Aktivni ogelj deluje kot močan adsorbens in na sebe veže niz snovi, zlasti pa purinske in pirimidinske derivate, z zelo visoko afiniteto. Na ta način se nepovratno odstranjuje sečna kislina, kot tudi drugi purinski in pirimidinski derivati, ker aktivni ogelj ima visoko moč adsorpcije za te snovi, ki je odvisna od koncentracije aktivnega oglja, minimalnega časa izpostavljanja, pa tudi fizičnih pogojev, kot je temperatura. Aktivno oglje se šteje za netoksično snov za človeški organizem, saj se skoraj sploh ne resorbira v digestivnem traktu, in se je uporabljalo kot terapija pri različnih zastrupitvah, zlasti s težkimi kovinami. Aktivno oglje je zelo močan adsorbens, saj je znano, da ima 1g aktivno ploščino okrog 1000m2. 0 učinkovitosti aktivnega oglja priča podatek, da se tudi voda za pitje čisti z uporabo filtra z aktivnim ogljem, ter je to tudi dokaz, da je aktivno oglje ena izmed najmanj toksičnih snovi.The technique of isolation of purine bases and nucleotides with activated carbon has proven to be useless in research conditions, since the generation of adsorption of uric acid and purine bases is so stable that they cannot be eluted from the adsorbent even with more aggressive treatments (such as NaOH). , or detect and quantify. This is precisely the moment which in our conditions of separation of uric acid from milk is useful because such a high affinity makes it impossible to release purine bases and uric acid from milk and therefore has maximum effect. Activated charcoal acts as a strong adsorbent and binds a number of substances, in particular purine and pyrimidine derivatives, with very high affinity. In this way uric acid, as well as other purine and pyrimidine derivatives, is irreversibly removed because activated charcoal has a high adsorption power for these substances, which depends on the concentration of activated charcoal, minimum exposure time, as well as physical conditions such as temperature. Activated charcoal is considered to be a non-toxic substance for the human body, since it is hardly absorbed in the digestive tract at all and has been used as a therapy for various poisonings, in particular heavy metals. Activated charcoal is a very strong adsorbent since 1g is known to have an active surface of around 1000m 2 . The effectiveness of activated charcoal is evidenced by the fact that drinking water is also purified using a activated carbon filter, and this is also evidence that activated carbon is one of the least toxic substances.
Tudi sedaj se uporabljajo tablete aktivnega oglja pri terapiji različnih zastrupitev, pa tudi pri terapiji hiperlipidemija, saj na sebe veže tudi lipide, zlasti pa holesterol. Nekoč, ko ni bilo zdravil za terapijo putike, se je aktivno oglje omenjalo v literaturi kot način terapije, toda takrat so se uporabljale velike doze, saj je bilo potrebno zagotoviti stalno prisotnost aktivnega oglja v digestivnem traktu. Jemale so se velike količine, do 35g dnevno, toda na ta način se je zagotavljala samo trenutna eliminacija sečne kisline iz digestivnega trakta. Vsakodnevno uživanje tolikšne količine aktivnega oglja je težko in nesmiselno, ker se le-ta hitro izloči s peristaltiko. Razen odstranjanja purinskih in pirimidinskih nukleotidov, se z delovanjem aktivnega oglja odpravljajo tudi nekatere neželjene vonjave, ki izhajajo od vodonik sulfidov. Zaradi tega se aktivno oglje ne uporablja rutinsko niti v terapiji hiperlipidemija, čeprav se je pokazalo, da zmanjšuje tudi do 30% vrednost holesterola in aterogenih lipoproteidov v krvi.Even now, activated carbon tablets are used in the treatment of various poisonings, as well as in the treatment of hyperlipidemia, since it also binds lipids, and especially cholesterol. Once there was no cure for pathotherapy, activated charcoal was mentioned in the literature as a therapy, but at that time large doses were used as it was necessary to ensure the continued presence of activated charcoal in the digestive tract. Large quantities were taken, up to 35g per day, but in this way only the immediate elimination of uric acid from the digestive tract was ensured. Consumption of so much activated charcoal on a daily basis is difficult and pointless because it is quickly eliminated by peristalsis. In addition to the removal of purine and pyrimidine nucleotides, some of the unwanted odors derived from hydrogen sulfides are eliminated by the action of activated carbon. As a result, activated carbon is not routinely used in hyperlipidemia therapy, although it has been shown to reduce up to 30% in blood cholesterol and atherogenic lipoproteids.
Upoštevajoč vsa navedena spoznanja smo prišli na idejo, da uporabimo aktivno oglje kot način vezave sečne kisline in purinskih derivatov v mleku. Dodatni učinek je vezava težkih kovin, pa tudi lipidov, kar je v tem dietskem izdelku pozitiven učinek, glede na to, da toksične kovine prispevajo k poškodbi tubula in s čemer je sekrecija sečne kisline na ravni tubula ledvice otežana, lipidi pa so eden izmed vzrokov sekundarne hiperurikemije v stanjih debelosti in diabetesa.Considering all the above findings, we came up with the idea to use activated carbon as a way of binding uric acid and purine derivatives in milk. An additional effect is the binding of heavy metals as well as lipids, which is a positive effect in this dietary product, since toxic metals contribute to tubule damage and make uric acid secretion at the kidney tubule level difficult, and lipids are one of the causes secondary hyperuricemia in obesity and diabetes.
V smislu supstitucije aditiva, predlagan proizvod podrazumeva kompozitni dietetski mlečni izdelek. Predlagana formula se lahko modificira v odnosu na obliko napitka (mleko ali fermentirani mlečni napitek-jogurt). Mleko je lahko v obliki tekočine ali kondenziranega kompozitnega mleka. V opisu tehnoloških postopkov faz separacije sečne kiseline, kot tudi drugih purinskih in pirimidinskih derivatov, se opravlja z metodo adsorpcije z aktivnim ogljem.In terms of additive substitution, the proposed product is a composite diet milk product. The proposed formula may be modified in relation to the form of the beverage (milk or fermented milk yogurt). The milk may be in the form of liquid or condensed composite milk. In the description of the technological procedures for the stages of separation of uric acid, as well as other purine and pyrimidine derivatives, it is carried out by the activated carbon adsorption method.
Dietetska upravičenost izuma: 0 možnem pomenu novih mlečnih izdelkov najbolje priča podatek, da je FDA (Food and Drug Administration program) najavil svoja pričakovanja, da bo v “prihodnosti mleko postalo funkcionalna hrana, katero bodo konzumenti izbirali po svojih potrebah. Poleg tega je 21. stoletje stoletje funkcionalne hrane in stoletje genomike. V tem smislu ima nutrigenomika, kot del genomike, svoje mesto v funkcionalni hrani, ker razvoj sodobnih znastvenih trendov, kot je nutrigenomika, odpirajo možnost sodobnega dietnega pristopa. Ta pristop bo z vsakodnevno prehrano lahko pomembno oblikoval individualno predispozicijo k boleznimi in s tem preprečiti prediktivno tveganje za obolevanje.Dietary Injustice of the Invention: The potential importance of new dairy products is best evidenced by the fact that the FDA (Food and Drug Administration Program) has announced its expectation that in the future, milk will become functional food that consumers will choose for their needs. In addition, the 21st century is the century of functional food and the century of genomics. In this sense, nutrigenomics, as part of genomics, has its place in functional foods, because the development of modern scientific trends, such as nutrigenomics, open the possibility of a modern dietary approach. This approach will be able to significantly shape the individual's predisposition to disease through daily diet, thereby preventing the predictive risk of disease.
Putika je relativno pogosta bolezen, nastaja s nalaganjem sečne kisline in njenih soli v sklepih in v drugih delih organizma, pretežno ledvicah. Prevalenca putike v razvitih državah je večja, tekom 1999 leta je incidenca v Ameriki znašala 41 obolelih na 1000, v Angliji pa celo 14 obolelih na 1000. Domneva se, da je samo v Ameriki okrog 5 milijonov obolelih. Ameriški podatki kažejo, da okrog 10% oseb ima hiperurikemijo, toda kdaj in pri kateremu od njih se bo razvila putika, se ne more z gotovostjo predvideti. Putika je bolezen, ki je v porastu. Osebe nad 65 let spadajo v močno predisponirano populacijo. Pri mlaših ljudeh putika običajno nastane kot posledica prirojenih defektov alosterijske regulacije sinteze purina, tako da enormno sintezo spremlja kot posledica enormna razgradnja, ali Leech-Nyhan sindrom, nastal kot deficit encima HGPRT transferaze. Od putike večinoma zbolijo moški, saj je odnos obolelih moških v primerjavi z ženskami okrog 9:1, toda zaradi pojavov sekundarne hiperurikemije zaradi debelosti ali diabetesa v poznejši življenski dobi, se odnos spremeni na 3,6:1. Pogosto je družinska bolezen. U takšnih družinah se nahajajo tudi člani, ki bolujejo od sladkorne bolezni, pretirane debelosti ali ledvičnih kamnov. Zaradi nalaganja sečne kisline in njenih soli uratov, nastanejo spremembe (deformacije) in propadanje sklepnega hrustanca, ki je trajno in v določenih primerih povzroča vse manjšo gibljivost sklepov, deformiteto, omejitve delovne in fizične sposobnosti. Čeprav je putika kronična bolezen, akutni napad putike nastopa v krizah. Pacienti, ki imajo putiko, kažejo tudi niz spremljajočih komorbiditetov, kot so koronarna bolezen, hipertenzija, dijabetes in ledvične bolezni. Smatra se, da je hiperurikemija tukaj sekundarnega značaja.Putica is a relatively common disease, caused by the loading of uric acid and its salts in the joints and in other parts of the body, mainly the kidneys. The prevalence of pathogens in developed countries is higher; in 1999, the incidence in America was 41 patients per 1000, and in England as many as 14 patients per 1000. It is estimated that there are around 5 million people in America alone. US data show that about 10% of people have hyperuricemia, but when and by whom a lump develops, it cannot be predicted with certainty. Putica is a growing disease. Persons over 65 belong to a strongly predisposed population. In young people, putic is usually caused by congenital defects in the allosteric regulation of purine synthesis, accompanied by enormous synthesis as a result of enormous degradation, or Leech-Nyhan syndrome resulting from a deficiency of the HGPRT transferase enzyme. Most people get sick with gout because the ratio of diseased men to women is about 9: 1, but due to the onset of secondary hyperuricemia due to obesity or diabetes in later life, the ratio changes to 3.6: 1. It is often a family illness. Such families also include members suffering from diabetes, obesity or kidney stones. Due to the loading of uric acid and its urea salts, changes (deformations) occur and the collapse of articular cartilage, which is permanent and in some cases causes less and less joint mobility, deformity, limitations of working and physical ability. Although gouty is a chronic disease, an acute gouty attack occurs in crises. Patients who have puticosis also show a set of accompanying comorbidities such as coronary disease, hypertension, diabetes and kidney disease. Hyperuricemia is considered to be of secondary character here.
Podatki, ki so objavljeni v časopisu Nev/ England Journal of Medicine o vplivu nutritivnih faktorjev na razvoj putike kažejo, da je incidenca putike manjša pri osebah, ki uživajo obrano mleko, z manj maščobe. To je tudi logično, če se upošteva podatek da je ksantin oksidaza locirana prav v mastnih kapljicah. Naši podatki potrjujejo nižjo raven sečne kisline v takšnem mleku.Večina spletnih strani in navodil o pravilni prehrani pri pacientih s putiko ali s sekundarno hiperurikemijo, priporoča mleko kot dovoljeno živilo in se nahaja na listah takoimenovane „apurinske dijete. Ali je to tudi res? Vsekakor ne, iz več razlogov. Upoštevajoč tako veliko pogostost oboljenja, potencijalna tveganja, ki jih nosi s seboj, kot tudi pomen mleka kot edinega živila, ki je izvor polnovrednih beljakovin, se vsiljuje potreba za proizvodnjo cele linije mlečnih dietetskih izdelkov, namenjenih tej populaciji. Pomen omenjenih aditivov je prikazan v literaturi, pri čemer je dokazano, da osebe, ki spijejo dnevno vsaj 1.500 miligramov C vitamina zmanjšajo tveganje obolevanja za putike za 45 procentov, v primerjavi s tistimi, ki zaužijejo manj kot 250 miligramov tega vitamina dnevno. Konzim Q10 (ubihinon, ubidekarenon, koenzim Q), je pomemben koenzim respiratorne verige mitohondrija, pa tudi močen antioksidans. Dokazano je, da je koristen učinek v terapiji s koenzimom Q10 prisoten zlasti pri pacientih s koronarno boleznijo, hipertenzijo in srčno insuficijenco.Data published in the Nev / England Journal of Medicine on the effect of nutritional factors on the development of lumps indicate that the incidence of lumps is lower in people consuming skim milk with less fat. This is also logical given the fact that xanthine oxidase is located right in the fat droplets. Our data confirm a lower level of uric acid in such milk. Most websites and instructions for proper nutrition in patients with gouty or secondary hyperuricemia recommend milk as a permitted food and be found on the sheets of the so-called 'apurine diet'. Is this also true? Certainly not, for several reasons. Considering both the high incidence of the disease, the potential risks it carries, and the importance of milk as the sole food source of whole protein, the need to produce a whole line of dairy diets for this population is imposed. The importance of these additives has been shown in the literature, showing that people who drink at least 1,500 milligrams of vitamin C daily reduce their risk of developing pathogens by 45 percent, compared to those who consume less than 250 milligrams of this vitamin per day. The Q10 enzyme (ubiquinone, ubidecarenone, coenzyme Q) is an important mitochondrial respiratory chain coenzyme as well as a potent antioxidant. A beneficial effect in coenzyme Q10 therapy has been shown to be particularly present in patients with coronary artery disease, hypertension and heart failure.
Upoštevajoč škodljivi učinek prostih radikalov pri adultnih osebah, se zastavlja vprašanje, kako preprečiti delovanje ksantin oksidaze v kravjem mleku. Encim v kravjem mleku je zelo obstojen in ga lahko uniči šele sterilizacija na 80°C, ki traja najmanj 10 s, oziroma UHT sterilizacija. V kolikor je encim ostal prisoten, zaradi oksidacijskega delovanja spremeni in okus in organoleptične lastnosti mleka. Ne tako redko, meritev delovanja ksantin oksidaze v mleku lahko da lažno nizke rezultate, ker je enzim lokaliziran v specifičnih mlečnomaščobnih globulah, najpogosteje v tem okolju zavarovan in neaktiven, tako da je nedostopen za meritve aktivnosti. Procesi homogenizacije povzročajo razdiranje mlečnomastnih globul, ko se sporošča encim in je dejaven producent prostih radikalov. Dočim sveže mleko ima v povprečju aktivnost okrog 50-60 IJ/L, mastni del mleka ima aktivnost okrog 200 IJ/L. V zvezi s tem se je koncem osemdesetih let prejšnjega stoletja razvila teorija o direktnem aterogenem efektu in povečanem kardiovaskularnem tveganju v primeru uživanja homogeniziranega mleka, glede na to, da se dostopna ksantin oksidaza lakho tudi resorbira in v cirkulaciji iskaže direktne toksične efekte na endotel ožilja. Posebej so občutljive celične strukture, ki vsebujejo sastvljene lipide plazmalogene.Considering the detrimental effect of free radicals in adults, the question is how to prevent the action of xanthine oxidase in cow's milk. The enzyme in cow's milk is very persistent and can only be destroyed by sterilization at 80 ° C for at least 10 s or UHT sterilization. If the enzyme is present, it changes the taste and organoleptic properties of the milk due to its oxidizing action. Not so infrequently, measuring the action of xanthine oxidase in milk can give false low results because the enzyme is localized in specific milk-fat globules, most often secured and inactive in this environment, so it is inaccessible for activity measurements. Homogenization processes cause the breakdown of fat-globules when the enzyme is released and is an active producer of free radicals. I breastfeed fresh milk has an average activity of about 50-60 IJ / L, the fat part of the milk has an activity of about 200 IJ / L. In this regard, the theory of direct atherogenic effect and increased cardiovascular risk of consuming homogenized milk developed in the late 1980s, given that the available xanthine oxidase also readily resorbs and has direct toxic effects on vascular endothelium in circulation. Particularly sensitive are cellular structures that contain assembled lipids plasmalogens.
Opis izvedbenega primeraDescription of an embodiment
Podroben opis priprave proizvoda je dan po etapah skozi katere gre mleko v mlekarni, začevši od prevzemanja na zbirnih mestih.A detailed description of the preparation of the product is given by the stages through which milk is passed through the dairy, starting from collection at collection points.
Faza I Primarna faza: Za tehnološki postopek procesiranja mleka v mlekarnah se vzame mleko, pridobljeno z molžo zdravih, pravilno hranjenih in redno molženih krav ali koz, najmanj 15 dni pred in 5 dni po otelitvi, ki se mu ne sme nič predhodno dodati ali odvzeti. Povprečna kemijska sestava kravjega mleka domače pisane rase je: voda (87,3%) in suha snov (12,7%). Suha snov vsebuje: proteine, vglavnem kazein (3,55%); maščobe (3,8%); laktozo (4,7%); mineralne snovi (0,65%). Kislost ne sme biti večja od 7,60 SH, da je hranjeno na optimalno nizki temperaturi in da je mikrobiološko ispravno, svojstvenega vonja in okusa. Mleko se dobiva iz zbirne mlekarne.Phase I Primary Phase: Milk obtained from the milking of healthy, properly fed and regularly milked cows or goats is taken for the technological process of milk processing in dairies, at least 15 days before and 5 days after hatching, with nothing previously added or withdrawn . The average chemical composition of cow's milk of domestic breed is: water (87.3%) and dry matter (12.7%). The dry matter contains: proteins, mainly casein (3.55%); fat (3.8%); lactose (4.7%); mineral substances (0.65%). The acidity should not exceed 7.60 SH, that it is stored at an optimum low temperature and that it is microbiologically correct, having an inherent odor and taste. Milk is obtained from a collective dairy.
Faza II Faza eliminacije sečne kisline, nukleinskih kislin in nukleotidov: V tej fazi se prične tehnološki postopek separacije sečne kisline in purina, tako da se iz dobljene količine mleka, ki se pripravlja za distribucijo, lahko vzame 1L mleka. V mleko se doda granulirano aktivno oglje (kokosovo) v količini 30 -100 g na en liter mleka, tj. 5% do 10% Mleko se meša in se pusti, da stoji okrog 2-4 ure na temperaturi od 25-30°C.Phase II Phase of elimination of uric acid, nucleic acids and nucleotides: At this stage, a technological process of separating uric acid and purine is started so that 1L of milk can be taken from the resulting volume of milk being prepared for distribution. Granulated activated carbon (coconut) in the amount of 30-100 g per liter of milk is added to the milk, ie. 5% to 10% The milk is stirred and left to stand for 2-4 hours at a temperature of 25-30 ° C.
Faza III Homogenizacija. Mleko se podvrže procesu homogenizacije, cilj pa je povečanje stabilnosti mlečne emulzije z zmanjšanjem povprečnega premera mastnih globul. To je rutinska procedura procesiranja mleka, ki omogoča boljšo in daljšo adsorpcijo. V nadaljnjem tekstu je posebej obdelan aspekt homogenizacije kot neugoden faktor v smislu sproščanja encima ksantin oksidaze iz neaktivne forme in so zaradi tega nekateri od aditivov dodani prav z namenom inhibicije ksantin oksidaze, ki se pri tem sprošča iz mastnih globul in postaja aktivna v produkciji sečne kisline.Phase III Homogenization. The milk undergoes a homogenization process and aims to increase the stability of the milk emulsion by reducing the average diameter of the fat globules. This is a routine milk processing procedure that allows for better and longer adsorption. In the following, the homogenisation aspect is specifically addressed as an unfavorable factor in the release of the xanthine oxidase enzyme from the inactive form and therefore some of the additives are added specifically to inhibit xanthine oxidase, which is released from fat globules and becomes active in uric acid production. .
Glede na to, da je aktivni ogelj že prisoten, se bo vsaka novonastala količina sečne kisline, vezala.Given that activated charcoal is already present, any newly formed amount of uric acid will bind.
Faza IV Standardizacija maščob v mleku do 0,5%. Kravje mleko vsebuje odvisno od rase in individualnih lastnosti goveda, med 2,5 in 6,0% mlečne maščobe, tako, da je mlečna maščoba obvezna sestavina mleka. Predlagani izdelek mora vsebovati 0,5% mlečne maščobe. Do tega predloga smo prišli na osnovi raziskav o vsebini sečne kisline v vzorcih pasteriziranega ali UHT mleka, ki sta prisotna na domačem tržišču. Analizirani so vzorci mleka ranga od 3,2% do 0,5% mlečne maščobe in je ugotovljeno, da je najnižja raven sečne kisline v vzorcih, ki imajo najmanj maščobe. To je tudi logično, če se upošteva podatek, da je ksantin oksidaza locirana prav v mastnih kapljicah. Za ločevanje mlečne maščobe se uporablja centrifugalni separator. Ločevanje m.m. temelji na razliki specifične mase m.m. in ostalih komponent mleka (0.93g/cm3 proti 1.032 g/cm3). Predlagani mlečni napitak vsebuje 0,5% mlečne maščobe. Proces se imenuje „in line“ standardizacija maščobe v mleku in se sestoji iz naslednjih elementov: transmiter gostote, transmiter pretoka, kontrolni ventil, kontrolna plošča in ventil za izklop. Gre za standardni aparat, ki ga ima vsaka mlekarna, ki se ukvarja s proizvodnjo mlečnih izdelkov. Konkretni aparat je opisan na osnovi tega, s čimer razpolaga Niška mlekarna.Phase IV Standardization of fat in milk up to 0.5%. Cow's milk contains between 2.5 and 6.0% of milk fat depending on race and individual characteristics of cattle, so that milk fat is a mandatory component of milk. The proposed product should contain 0.5% milk fat. We came up with this proposal based on research on uric acid content in samples of pasteurized or UHT milk present on the domestic market. Milk samples ranging from 3.2% to 0.5% milk fat were analyzed and found to be the lowest uric acid level in the samples with the least fat. This is also logical given the fact that xanthine oxidase is located right in the fat droplets. A centrifugal separator is used to separate the milk fat. The separation of mm is based on the difference of the specific mass of mm and other milk components (0.93g / cm 3 vs 1.032 g / cm 3 ). The proposed milk beverage contains 0.5% milk fat. The process is called 'in line' standardization of fat in milk and consists of the following elements: density transmitter, flow transmitter, check valve, control panel and shut-off valve. It is a standard appliance that every dairy company has to deal with producing dairy products. The concrete apparatus is described on the basis of what is available to Nis Dairy.
Faza V: Eliminacija aktivnega oglja: Mleko se procesira v baktofugu, ko se s procesom centrifugiranja izvrže tudi aktivno ogelje, saj večji delci sedimentirajo. V dodatek za baktofugo se uporablja tudi filter KOFIL S5/100 (mm/g/m2), skozi katerega se prepušča mleko, potem pa skozi Watman papir, na katerem končno ostanejo tudi najbolj drobni delčki aktivnega oglja. Baktofuga je sicer aparat, ki se uporablja samo za odstranjevanje bakterij, nesnage in spor, kar je njen standardni namen v procesu industrijske predelave mleka.Phase V: Activation of activated charcoal: Milk is processed in a bactofugus when activated charcoal is also expelled by the centrifugation process as larger particles are sedimented. A KOFIL S5 / 100 filter (mm / g / m 2 ) is also used in the Bactofugus additive, through which milk is passed, and then through Watman paper, on which even the finest particles of activated carbon are left. Baktofuga is an apparatus used solely for the removal of bacteria, dirt and spores, which is its standard purpose in the process of industrial milk processing.
Faza VI: Dodatek aditivov: Potem, ko je pridobljeno mleko z reducirano vsebino sečne kisline, nukleinskih kislin in purina, se dodajo predlagani aditivi. Gre za hidrosolubilne snovi, ki se dobro raztapljajo v vodi, s tem pa tudi v mleku. Na osnovi njihovih fizikokemijskih lastnosti je ugotovljeno, da pri raztapljanju ni nikakršne interakcije s sestavinami mleka. Predlagani aditivi so:Phase VI: Additive Supplementation: After the milk with reduced uric acid, nucleic acid and purine content is obtained, the proposed additives are added. These are hydro solubilizers that dissolve well in water and therefore also in milk. Based on their physicochemical properties, it is found that there is no interaction with the constituents of the milk when dissolved. The suggested additives are:
• Vitamin C-L-askorbinska kislina 800 do 1200, prednostno 1000mg/l • Koenzim Q10 (naravnega porekla) 100 do 300, prednostno 200mg/l • L - arginin 400 do 600, prednostno 500 mg/l• Vitamin C-L-ascorbic acid 800 to 1200, preferably 1000mg / l • Coenzyme Q10 (natural origin) 100 to 300, preferably 200mg / l • L - arginine 400 to 600, preferably 500 mg / l
Vzame se količina mleka 1L in se v njega doda L-askorbinska kislina, Koenzim Q in Larginin v predpisani količini, potem pa se vzorec meša, da bi se dosegla popolna raztopljivost. V kolikor se vzame začetna večja količina mleka, se koncentarcija dodatih aditivov preračunava po formuli:The quantity of milk 1L is taken and L-ascorbic acid, Coenzyme Q and Larginin added in the required amount, and then the sample is stirred to achieve complete solubility. If the initial larger quantity of milk is taken, the concentration of additives added is calculated by the formula:
priporočena doza x število litrov mlekarecommended dose x number of liters of milk
Upoštevajoč podatek, da tudi laktoza kaže malo stopnjo adsorpcije na aktivno ogelje, so njene vrednosti nekaj nižje kot v standardnih mlečnih izdelkih, kar je ugodno pri pacientih z diabetesom in debelstjo.Considering the fact that lactose also shows a low degree of adsorption on activated charcoal, its values are slightly lower than in standard dairy products, which is favorable for patients with diabetes and obesity.
Faza VII: Dezodorizacija. S pomočjo parcialnega vakuuma se iz mleka odstranijo neželene vonjave, kar je običajni postopek. Dodajanje aktivnega oglja je ugodno v tej metodi, saj se aktivno oglje uporablja tudi z namenom odstranjevanja neželenih vonjav.Phase VII: Deodorization. Partial vacuum eliminates unwanted odors from milk, which is a normal procedure. The addition of activated charcoal is advantageous in this method, since activated charcoal is also used to eliminate unwanted odors.
Faza Vlil: UHT sterilizacija: Pod sterilizacijo se razume, da je mleko predhodno homogenizirano, ohlajeno na temperaturi od 4 do 1°C, prečiščeno in najpozneje 24 ur po molži zagrevano na temperaturi od 135 do 150°C, toliko časa, da se zagotovi sterilizacija, potem pa se ohladi in polni v aseptičnih pogojih. Tekom UHT sterilizacije ne prihaja do sprememb fizikokemijskih lastnosti omenjenih vitaminov, prihaja pa do nepovratne inhibicije ksantin oksidaze. Gre za standardni postopek, ki ga izvaja vsaka mlekarna, tako, da tega koraka ni potrebeno opisovati, saj ni nov, niti spremenjen.Phylum Vlil: UHT Sterilization: Sterilization is understood to mean that milk is pre-homogenized, cooled to 4 to 1 ° C, purified and heated to 135 to 150 ° C for a maximum of 24 hours after milking, to ensure sterilization, then cooled and charged under aseptic conditions. UHT sterilization does not alter the physicochemical properties of these vitamins, and irreversible inhibition of xanthine oxidase occurs. This is a standard procedure performed by each dairy, so this step does not need to be described as it is neither new nor changed.
V fazah preizkušanja stopnje adsorpcije aktivnega oglja smo posebno pozornost usmerili na efekte naslednjih faktorjev: koncentracije aktivnega oglja v mleku, dolžino izpostavljanja mleka in temperaturo. V vsaki od teh variabil, mehanično tresenje mleka prispeva k boljši adsorpciji, kar je tudi v osnovi samega fizičnega procesa adsorpcije. V tabeli 2 in shemi 1 je dan prikaz različnih fizičnih vpivov na skrajno-rezidualno količino sečne kisline v mleku. Lahko se nedvomno potrdi, da dolžina izpostavljanja mleka in temperatura imajo mnogo več vpliva kot količina prisotne mlečne maščobe. To se lahko pričakuje, saj je adsorptivna površina aktivnega oglja velika, tako da prisotne maščobe ne kompetirajo v pomembnejši meri. V eksperimentu so uporabljena mleka z visoko vsebnostjo maščobe. Najboljše rezultate dobimo, ko je mleko 4 ure v aktivnem procesu adsorbcije na temperaturi do 37°C.In the phases of testing the rate of adsorption of activated carbon, particular attention was paid to the effects of the following factors: the concentration of activated carbon in milk, the length of milk exposure and temperature. In each of these variables, mechanical shaking of the milk contributes to better adsorption, which is also the basis of the physical adsorption process itself. Table 2 and Scheme 1 give an overview of the different physical influences on the residual amount of uric acid in milk. It can be undoubtedly confirmed that the length of milk exposure and temperature have far more influence than the amount of milk fat present. This can be expected since the adsorptive surface of activated charcoal is large so that the fat present does not compete to a significant degree. The experiment uses high fat milk. Best results are obtained when the milk is in the active adsorption process at temperatures up to 37 ° C for 4 hours.
Faza IX : Polnjenje in zapiranje embalaže. Predvideno je pakiranje v nepovratni kartonski embalaži. Najbolj primerna kartonska embalaža je tetra-pak ali tetra-brik. Ovoj in originalno pakiranje je prikazano na sl.4. Pakiranje naj bi bilo v embalaži s katero se zagotovi originalnost izdelka. Ko se navedeni izdelek spravlja v promet v originalnem pakiranju, bi morala deklaracija vsebovati naslednje podatke:Phase IX: Filling and sealing of packaging. Packaging in non-returnable cardboard packaging is foreseen. The most suitable cardboard packaging is tetra-pack or tetra-brisk. The wrapping and the original packaging are shown in Fig.4. The packaging should be in a package that guarantees the originality of the product. When the said product is marketed in its original packaging, the declaration should include the following information:
1) naziv izdelka1) product name
2) naziv in sedež proizvajalca2) name and registered office of the manufacturer
3) datum proizvodnje in rok trajanja,3) date of manufacture and shelf life,
4) neto količina (zapremina) pakiranja4) net quantity (volume) of packaging
5) seznam sestavin in dodani aditivi (Tabela 3 prikazuje deklaracijo dobljenega proizvoda z opisanim tehnološkim postopkom. Deklaracija vsebuje količino proteinov, sladkorjev, maščobe in količino sečne kisline, purinskih nukleotidov, koncentracijo dodanega vitamina C, koencima Q10 in arginina.5) ingredient list and additives added (Table 3 shows the declaration of the obtained product by the described process. The declaration contains the amount of protein, sugars, fat and amount of uric acid, purine nucleotides, concentration of added vitamin C, coenzyme Q10 and arginine.
6) pogoji shranjevanja6) storage conditions
Na sliki 1 je prikazan KROMATOGRAM MLEKA- tretman T4: mleko v procesu adsorbcije 4h na 25-30oC (OT ne tretirano, 6T tretirano kot 10% sestavaj-analizirano s HPLC in sicer so na sliki 1a Kromatogrami vzorca določeni pri A=254nm, na sliki 1b pa so Iromatogrami vzorca določeni pri A=280nm (za sečno kislino).Figure 1 shows the CHROMATOGRAM OF MILK- T4 treatment: milk in the process of adsorption 4h at 25-30oC (OT not treated, 6T treated as 10% of the composition-analyzed by HPLC, in Figure 1a The sample chromatograms are determined at A = 254nm, at and in Fig. 1b, the Iromatograms of the sample are determined at A = 280nm (for uric acid).
V nadaljevanju so prikazane tabeleThe tables below are shown
Tabela 1. Odstotek sečne kisline v kravjem mleku po različnih nadmorskih višinah pridelave:Table 1. Percentage of uric acid in cow's milk at different altitudes of production:
Tabele 2a, b in c. Odstotek sečne kisline in derivatov purina v odvisnosti od postopka obdelave z ogljenim filtromTables 2a, b and c. Percentage of uric acid and purine derivatives depending on the carbon filter treatment process
a) Kozje mleko - Slovenijaa) Goat milk - Slovenia
Xyp +Xyp +
b) Alpsko mleko - Slovenijab) Alpine milk - Slovenia
c) Mleko (Z bregov) Slovenijac) Milk (From the banks) Slovenia
Legenda:Legend:
H..............mleko na hladnem (H2 2 uri, H4 4 ure)H .............. milk in the cold (H2 2 hours, H4 4 hours)
T..............termično obdelano mleko of 25-30°C (T2 2 uri, T4 4 ure)T .............. 25-30 ° C heat treated milk (T2 2 hours, T4 4 hours)
Številke spredaj predstavljajo odstotek aktivnega oglja:The numbers in the front represent the percentage of activated carbon:
OH in OT je brez tretiranja z aktivnim ogljem.OH and OT are free of activated carbon treatment.
Številke 1, 2, 3, 4, 5 pred H ali T pomenijo:, 1%,2%,3%,4%,5% odsotek aktivnega oglja 6T pomeni 10% .The numbers 1, 2, 3, 4, 5 before H or T represent :, 1%, 2%, 3%, 4%, 5% the percentage of activated carbon 6T means 10%.
Tipi mleka:Milk types:
Kozje mleko -(z bregov) Vindija, uvoznik ERFA Ljubljana 3,0% mlečne masti;Goat's milk - (from the banks) Vindija, importer of ERFA Ljubljana 3.0% milk fat;
2) Alpsko mleko- Polno alpsko mleko, 3,5% maščobe (Ljubljanske mlekarne);2) Alpine milk - Full Alpine milk, 3.5% fat (Ljubljanske mlekarne);
3) Mleko Spar 3,5% mlečne maščobe3) Spar milk 3.5% milk fat
Tabela 3. Predstavljena dietetska formula mlečnega napitkaTable 3. Dietary formula of milk beverage presented
Dr. Jure)Marn Patentnii zastopnikDr. Jure) Marn Patentnii Agent
Za prof.d/·. A vrelija CencičFor Prof.d / ·. And the hotter Cencić
Claims (5)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200900262A SI23130A (en) | 2009-09-24 | 2009-09-24 | Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds |
| EP10779348A EP2490547A1 (en) | 2009-09-24 | 2010-09-22 | Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds |
| PCT/SI2010/000053 WO2011037545A1 (en) | 2009-09-24 | 2010-09-22 | Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200900262A SI23130A (en) | 2009-09-24 | 2009-09-24 | Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI23130A true SI23130A (en) | 2011-03-31 |
Family
ID=43302983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200900262A SI23130A (en) | 2009-09-24 | 2009-09-24 | Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2490547A1 (en) |
| SI (1) | SI23130A (en) |
| WO (1) | WO2011037545A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113439846A (en) * | 2021-05-26 | 2021-09-28 | 石药集团中诺药业（泰州）有限公司 | Nutrient composition formula and health food for people with high uric acid and gout |
| CN113577254A (en) * | 2021-08-27 | 2021-11-02 | 四川力量科技有限公司 | Product for recovering gout and preparation method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB746834A (en) * | 1952-03-13 | 1956-03-21 | American Home Prod | Testing for a specific lactobacillus bifidus growth-promoting substance |
| FR1446105A (en) * | 1964-09-02 | 1966-07-15 | Asahi Chemical Ind | Method for purifying purineribonucleoside-5 'monophosphate |
| US6706287B2 (en) * | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| JPWO2004112809A1 (en) * | 2003-06-24 | 2006-07-20 | 大塚製薬株式会社 | Serum uric acid reducing composition |
| JP2006001898A (en) * | 2004-06-18 | 2006-01-05 | Chisso Corp | Purine body-adsorbing agent |
| CN1931187A (en) * | 2006-09-30 | 2007-03-21 | 廖建玲 | Application of high purity and high adsorption nanometer microporous charcoal powder in preparing medicine for treating uric acid disease |
-
2009
- 2009-09-24 SI SI200900262A patent/SI23130A/en not_active IP Right Cessation
-
2010
- 2010-09-22 EP EP10779348A patent/EP2490547A1/en not_active Withdrawn
- 2010-09-22 WO PCT/SI2010/000053 patent/WO2011037545A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011037545A1 (en) | 2011-03-31 |
| EP2490547A1 (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9757345B2 (en) | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes | |
| US11116779B2 (en) | Methods for modulating corticosterone levels in psychologically stressed individuals | |
| CA2903561C (en) | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein | |
| BRPI0713778A2 (en) | enriched infant formulas and uses | |
| TWI527581B (en) | Aseptically packaged nutritional liquids comprising hmb | |
| EP2672836A1 (en) | Liquid nutritional products comprising metal amino acid chelates | |
| CN113662199A (en) | Human milk oligosaccharides for preventing gastrointestinal damage and/or promoting gastrointestinal healing | |
| JP2015163074A (en) | Nutritional emulsions comprising calcium hmb and soluble protein | |
| CZ2004238A3 (en) | Enteral formulations | |
| JP2012523839A (en) | High fiber nutrition emulsion | |
| JP2012523840A (en) | High fiber nutrition emulsion for blood glucose control | |
| WO2022266058A1 (en) | Methods and compositions for treating gas | |
| JP2012523841A (en) | High fiber nutrition emulsion with glycerin | |
| SI23130A (en) | Composite dietetic milk draught and method for production of composite dietetic milk draught with reduced level of uric acid and purine compounds | |
| WO2014047493A1 (en) | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate and protein | |
| JP2007022989A (en) | Anti-fatigue agent | |
| ITPR20090057A1 (en) | TECHNOLOGICAL PROCEDURE FOR THE PRODUCTION OF A MILK DIETARY COMPOSITE FOOD PRODUCT WITH REDUCED LEVEL OF URIC ACID AND PURINE AND FOOD PRODUCT SO OBTAINED | |
| WO2023159093A1 (en) | Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin | |
| WO2024079471A1 (en) | Oligosaccharide composition for use in the reduction of the level of ammonia | |
| WO2022177965A1 (en) | Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin | |
| BR102019024770A2 (en) | protein compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OO00 | Grant of patent |
Effective date: 20110411 |
|
| KO00 | Lapse of patent |
Effective date: 20190926 |